The aim of this trial is to assess two novel and recently developed imaging modalities against the current standard of pelvic lymph node dissection (PLND) in the setting of suspected metastatic disease.

This will allow much more accurate staging of disease by enabling the detection of very small cancer deposits in lymph nodes that might have been missed by conventional imaging, or one modality alone (false negatives) and enable the identification of the location of these nodes. In addition, in the vast majority of men, we expect these imaging tests to return true negatives, allowing surgeons to confidently avoid having to perform a PLND.